⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AMRX News
Amneal Pharmaceuticals, Inc. Class A Common Stock
Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease
globenewswire.com
AMRX
IgE Receptor Antagonists Clinical Trial Pipeline Analysis: 12+ Key Companies Shaping the Future of IgE Receptor Antagonists Therapeutics | DelveInsight
globenewswire.com
AMRX
ARX
GSK
AZN
SNY
NVS
MRK
REGN
JNJ
PFE
BMY
LLY
VRTX
AMGN
ABBV
GILD
BIIB
CSL
AQST
RAPT
ALGT
Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution
globenewswire.com
AMRX
Metastatic HER2-Positive Breast Cancer Market Expected to Surge at a CAGR of 8.3% During the Forecast Period (2026–2036) Due to Advancing Targeted Treatments | DelveInsight
globenewswire.com
PFE
JNJ
AMRX
BOLT
BIIB
Amneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026
globenewswire.com
AMRX
From Ambrx to Oncolytics: Why Jared Kelly Believes the Market May Be Missing the Bigger Oncology Story
accessnewswire.com
AMRX
ONCY
Knox Systems and RapidFort Join Forces to Defend Against Mythos-Generated CVE Threats and Fast-Track FedRAMP Compliance
businesswire.com
ADBE
AMRX
Form 8-K
sec.gov
AMRX
Form 8-K
sec.gov
AMRX
Amneal Reports First Quarter 2026 Financial Results
globenewswire.com
AMRX